# Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

> **NCT05952128** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 50 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Fluzoparib+ Dalpiciclib

## Key facts

- **NCT ID:** NCT05952128
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952128, "Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05952128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*